Rapamycin-induced proteasome activation persists post‑treatment via epigenetic remodeling of autophagy‑related promoters

Hypothesis

Rapamycin treatment induces a durable increase in proteasome activity by promoting histone acetylation at the promoters of proteasome subunit genes, an effect that persists after drug clearance.

Rationale

• mTORC1 inhibition by rapamycin activates TFEB and ATF4, driving lysosomal and proteasome gene expression (https://www.gethealthspan.com/research/article/rapamycin-and-trametinib).
• Rapamycin also stimulates the ubiquitin‑proteasome system and restores autophagic flux, clearing protein aggregates (https://www.pnas.org/doi/10.1073/pnas.1521919112).
• Transient metabolic mimicry would predict loss of benefit after withdrawal, whereas persistent proteasome upregulation would indicate lasting repair (https://ubiehealth.com/doctors-note/rapamycin-longevity-science-mtor-inhib-lifespan-6721e2).
• Emerging evidence shows that nutrient‑sensing pathways can remodel chromatin via HDAC inhibition and HAT activation, suggesting a mechanistic bridge (https://pmc.ncbi.nlm.nih.gov/articles/PMC12766144/).

Novel Mechanistic Insight

We propose that rapamycin‑mediated mTORC1 suppression reduces phosphorylation of the histone acetyltransferase p300/CBP, increasing its activity at proteasome gene promoters. Concurrently, decreased S6K signaling lowers HDAC1 recruitment, resulting in a net gain of H3K27ac marks. This epigenetic state sustains transcription even when mTOR signaling rebounds after drug cessation.

Testable Predictions

1. Persistence – Mice treated with rapamycin for 8 weeks, then withdrawn, will retain elevated proteasome activity and reduced ubiquitin‑positive aggregates for at least 4 weeks post‑withdrawal compared with vehicle controls.
2. Epigenetic signature – ChIP‑seq will show increased H3K27ac at promoters of Psmb5, Psmc1, and Capn1 in withdrawn mice, matching levels seen during continuous treatment.
3. Causality – Pharmacological inhibition of p300/CBP (e.g., with A-485) during rapamycin exposure will block the persistent proteasome boost and abolish any lifespan extension after withdrawal.
4. Transcriptomic specificity – RNA‑seq will reveal a proteasome‑centric gene set that remains upregulated, whereas broader CR‑like metabolic genes revert to baseline.

Experimental Design

• Groups (n = 30 per group, male C57BL/6J):
  1. Vehicle control.
  2. Continuous rapamycin (14 mg/kg diet) for 12 weeks.
  3. Intermittent rapamycin: same dose for 8 weeks, then washout for 4 weeks.
  4. Rapamycin + p300/CBP inhibitor (A-485) during the 8‑week exposure, followed by washout.
• Readouts (at weeks 8, 12, 16):
  • Proteasome chymotrypsin‑like activity assay.
  • Quantification of insoluble ubiquitinated proteins by Western blot.
  • Lifespan monitoring (survival curves).
  • ChIP‑seq for H3K27ac at proteasome promoters.
  • RNA‑seq for pathway enrichment.
• Statistical plan – Two‑way ANOVA with factors treatment and time; post‑hoc Tukey; survival analyzed by log‑rank test.

Potential Outcomes

• Support – Withdrawn rapamycin mice show sustained proteasome activity, elevated H3K27ac, and extended lifespan comparable to continuous treatment; p300/CBP inhibition abolishes these effects.
• Refutation – Proteasome activity and histone acetylation return to baseline after withdrawal, and lifespan benefit disappears, indicating that mTOR inhibition’s longevity impact relies solely on metabolic mimicry.

Implications

If validated, this hypothesis would reframe rapamycin not merely as a caloric‑restriction mimetic but as an epigenetic reprogrammer that installs a durable proteostatic regime. It would suggest that intermittent dosing could achieve long‑term rejuvenation with reduced drug exposure, and that targeting chromatin regulators alongside mTOR inhibitors might amplify lasting repair mechanisms.